Click here to close now.

Welcome!

.NET Authors: Pat Romanski, Andreas Grabner, Trevor Parsons, Elizabeth White, Tad Anderson

News Feed Item

3SBio Inc. Announces Unaudited Third Quarter 2012 Results

Net revenues grew 22.5% year-on-year to RMB180.6 million (US$28.7 million)

/PRNewswire/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the

third quarter and nine months ended September 30, 2012.

SHENYANG, China, Nov. 11, 2012 Third Quarter 2012 Financial Highlights:

  • Total net revenues increased by 22.5% over the third quarter of 2012 to RMB180.6 million (US$28.7million), compared to RMB147.4 million (US$23.1 million) in the third quarter of 2011.
  • Operating income decreased by 5.1% to RMB38.1 million (US$6.1 million), compared to operating income of RMB40.1 million (US$6.3 million) in the third quarter of 2011.
  • GAAP net income attributable to 3SBio Inc. decreased by 34.5% to RMB22.1 million (US$3.5 million), compared to net income of RMB33.7 million (US$5.3 million) in the third quarter of 2011. Non-GAAP net income attributable to 3SBio Inc. decreased by 7.6% to RMB31.2 million (US$5.0 million), compared to net income of RMB33.7 million (US$5.3 million) in the third quarter of 2011.
  • GAAP net income attributable to 3SBio Inc. per American Depositary Share ("ADS") on a fully-diluted basis decreased by 35.3% to RMB0.97 (US$0.15) compared to net income per ADS on a fully-diluted basis of RMB1.50 (US$0.23) for the third quarter of 2011. Non-GAAP net income attributable to 3SBio Inc. per American Depositary Share ("ADS") on a fully-diluted basis decreased by 8.7% to RMB1.37 (US$0.22) compared to net income per ADS on a fully-diluted basis of RMB1.50 (US$0.23) for the third quarter of 2011.
  • Cash, cash equivalents and time deposits were RMB852.6 million (US$135.7 million, including restricted cash of RMB0.7 million) at September 30, 2012.

First Nine Months 2012 Financial Highlights:

  • Total net revenues increased by 26.0% over the first nine months of 2012 to RMB506.0 million (US$80.5 million), compared to RMB401.7 million (US$63.0 million) in the first nine months of 2011.
  • Operating income increased by 22.8% to RMB117.3 million (US$18.7 million), compared to operating income of RMB95.6 million (US$15.0 million) in the first nine months of 2011.
  • GAAP net income attributable to 3SBio Inc. decreased by 1.1% to RMB85.2 million (US$13.6 million), compared to net income of RMB86.2 million (US$13.5 million) in the first nine months of 2011. Non-GAAP net income attributable to 3SBio Inc. increased by 22.5% to RMB105.7 million (US$16.8 million), compared to net income of RMB86.2 million (US$13.5 million) in the first nine months of 2011.
  • GAAP net income attributable to 3SBio Inc. per ADS on a fully-diluted basis decreased by 1.8% to RMB3.76 (US$0.60) compared to net income per ADS on a fully-diluted basis of RMB3.83 (US$0.60) for the first nine months of 2011.  Non-GAAP net income attributable to 3SBio Inc. per ADS on a fully-diluted basis increased by 21.5% to RMB4.65 (US$0.74) compared to net income per ADS on a fully-diluted basis of RMB3.83 (US$0.60) for the first nine months of 2011.

Third Quarter 2012 Business Highlights

Operations

  • EPIAO, the Company's flagship injectable recombinant human erythropoietin (EPO) product, demonstrated strong growth with net revenue in the third quarter of 2012 rising 16.2% to RMB100.6 million (US$16.0 million), compared to RMB86.6 million (US$13.6 million) in the third quarter of 2011.
  • Net revenues for TPIAO, the Company's novel recombinant human thrombopoietin (TPO) product, increased by 24.2% to RMB 57.2 million (US$9.1 million) in the third quarter of 2012, compared to RMB46.0 million (US$7.2 million) in the third quarter of 2011.
  • Net revenues for Iron Sucrose Supplement increased by 27.8% to RMB9.1 million (US$1.4 million) in the third quarter of 2012, compared to RMB7.1 million (US$1.1 million) in the third quarter of 2011.
  • Net export revenues increased by 92.5% to RMB10.3 million (US$1.6 million), accounting for 5.7% of total net revenue in the third quarter of 2012, compared to RMB5.3 million (US$0.8 million), or 3.6% of net revenues in the third quarter of 2011. 

Dr. Jing Lou, chief executive officer of 3SBio, commented: 

"We remain optimistic about the long-term market potential for our core products, EPIAO and TPIAO, however, in the short term, the NDRC's cuts to retail drug price ceilings will put pressure on tender prices. The recently-completed military hospital tender resulted in price cuts in excess of 20% for both EPIAO and TPIAO but the impact on upcoming provincial tenders remains uncertain.  EPIAO and TPIAO volume growth remains strong as access to dialysis treatment in China continues to improve. Due to the growing demand for dialysis services, we recently started construction of a facility in Benxi, Liaoning Province, to manufacture dialysis-related consumables. The new facility is expected to commence operations in 2015/16. We will continue to look for opportunities to broaden our product lines to serve the needs of CKD patients."

Three Months Ended September 30, 2012 Unaudited Financial Results

Net revenues. Net revenues increased by 22.5% to RMB180.6 million (US$28.7 million) for the third quarter of 2012 from RMB147.4 million (US$23.1 million) for the same period in 2011. This increase was largely due to continued strong sales of EPIAO and TPIAO which grew by 16.2% and 24.2%, respectively, over the same period in 2011. TPIAO remained 3SBio's second largest revenue contributor in the quarter, accounting for 31.7% of total net revenues. Export sales increased by 92.5% year-on-year to RMB10.3 million (US$1.6 million), and revenues from Iron Sucrose rose by 27.8% year-on-year to RMB9.1 million (US$1.4 million).

Gross profit. As a result of continued sales growth from key products, gross profit for the third quarter of 2012 increased by 20.6% to RMB161.8 million (US$25.7 million) from RMB134.1 million (US$21.0 million) for the same period in 2011. Gross margins decreased 1.4% to 89.6% for the third quarter of 2012 from 91.0% for the same period in 2011. The decrease in gross margin was partly attributable to pricing pressure related to the National Development and Reform Commission's cuts to drug ceiling prices.

Operating expenses. Operating expenses were RMB123.8 million (US$19.7 million) for the third quarter of 2012, representing an increase of 31.6% from RMB94.0 million (US$14.7 million) for the same period in 2011.

  • Research and development ("R&D") costs.  R&D costs for the third quarter of 2012 were RMB21.1 million (US$3.4 million), or 11.7% of net revenues, compared to RMB10.6 million (US$1.7 million), or 7.2% of net revenues, for the same period in 2011. The increase in R&D expenses is primarily attributable to NuPIAO, our second generation version of EPIAO and an anti-TNF compound that targets rheumatoid arthritis, psoriasis and other inflammatory disorders.
  • Sales, marketing and distribution expenses.  Sales, marketing and distribution expenses for the third quarter of 2012 were RMB83.9 million (US$13.3 million), or 46.5% of net revenues, compared to RMB68.2 million (US$10.7 million), or 46.3% of net revenues, for the same period in 2011.
  • General and administrative expenses. General and administrative expenses for the third quarter of 2012 were RMB18.8 million (US$3.0 million), or 10.4% of net revenues, compared to RMB15.5 million (US$2.4 million), or 10.5% of net revenues for the same period in 2011.

Operating income. Operating income was RMB38.1 million (US$6.1 million) for the third quarter of 2012, a 5.1% decrease from operating income of RMB40.1 million (US$6.3 million) for the same period in 2011. GAAP operating margin for the third quarter of 2012 was 21.1%, a 6.1% point decrease from operating margin of 27.2% for the same period in 2011. The decrease in operating margin is primarily due to lower gross margins and higher R&D expenses.

Interest income. Net interest income was RMB5.8 million (US$0.9 million) for the third quarter of 2012, compared to RMB5.0 million (US$0.8 million) for the same period in 2011. The increase in interest income is primarily due to the combined effect of increased time deposits and higher interest rates on time deposits.

Net income attributable to 3SBio Inc. GAAP net income attributable to 3SBio Inc. was RMB22.1 million (US$3.5 million) for the third quarter of 2012, a 34.5% decrease over net income of RMB33.7 million (US$5.3 million) for the same period in 2011. Net income attributable to 3SBio Inc. per ADS on a fully-diluted basis for the third quarter of 2012 decreased to RMB0.97 (US$0.15) compared to RMB1.50 (US$0.23) for the same period in 2011. Net margin for the third quarter of 2012 was 12.1%, a 10.8% point decrease over net margin of 22.9% for the same period in 2011. 

Non-GAAP net income attributable to 3SBio Inc. was RMB31.2 million (US$5.0 million) for the third quarter of 2012, a 7.6% decrease over net income of RMB33.7 million (US$5.3 million) for the same period in 2011. Non-GAAP net income attributable to 3SBio Inc. per ADS on a fully-diluted basis for the third quarter of 2012 decreased to RMB1.37 (US$0.22) compared to RMB1.50 (US$0.23) for the same period in 2011. Net margin for the third quarter of 2012 was 17.3%, a 5.6% point decrease over net margin of 22.9% for the same period in 2011.

The difference between GAAP and non-GAAP net income is due a writedown in the third quarter of RMB 9.1 million (US$1.45 million) in available-for-sale securities, following a decline deemed to be other than temporary in the market value of 3SBio's US$4.5 million investment in the common shares of Isotechnika (TSX:ISA). The carrying value of the investment in Isotechnika as of September 30, 2012 was RMB7.9 million (US$1.3 million).

Nine Months Ended September 30, 2012 Unaudited Financial Results

Net revenues. Net revenues increased by 26.0% to RMB506.0 million (US$80.5 million) for the first nine months of 2012 from RMB401.7 million (US$63.0 million) for the same period in 2011. This increase was largely due to continued strong sales of EPIAO and TPIAO which grew by 20.9% and 26.6%, respectively, over the same period in 2011. TPIAO remained 3SBio's second largest revenue contributor in the first nine months, accounting for an all-time high of 31.5% of total net revenues. Export sales increased by 86.4% year-on-year to RMB26.3 million (US$4.2 million), and revenues from Iron Sucrose rose 42.1% year-on-year to RMB25.8 million (US$4.1 million).

Gross profit. As a result of continued sales growth from key products, gross profit for the first nine months of 2012 increased by 26.4% to RMB453.3 million (US$72.1 million) from RMB358.5 million (US$56.2 million) for the same period in 2011. Gross margins increased by 0.4% points to 89.6% for the first nine months of 2012 from 89.2% for the same period in 2011. The increase was mainly attributable to improved manufacturing productivity of the new plant.

Operating expenses. Operating expenses were RMB336.0 million (US$53.5 million) for the first nine months of 2012, representing an increase of 27.8% from RMB263.0 million (US$41.2 million) for the same period in 2011.

  • Research and development ("R&D") costs.  R&D costs for the first nine months of 2012 were RMB54.4 million (US$8.7 million), or 10.8% of net revenues, compared to RMB29.1 million (US$4.6 million), or 7.2% of net revenues, for the same period in 2011. The increase in R&D expenses is primarily attributable to NuPIAO, our second generation version of EPIAO and an anti-TNF compound that targets rheumatoid arthritis, psoriasis and other inflammatory disorders.
  • Sales, marketing and distribution expenses.  Sales, marketing and distribution expenses for the first nine months of 2012 were RMB227.3 million (US$36.2 million), or 44.9% of net revenues, compared to RMB188.9 million (US$29.6 million), or 47.0% of net revenues, for the same period in 2011.  The decrease is mainly attributable to improved sales force productivity following the expansion of the sales force in 2010 and 2011.
  • General and administrative expenses. General and administrative expenses for the first nine months of 2012 were RMB55.0 million (US$8.8 million), or 10.9% of net revenues, compared to RMB46.5 million (US$7.3 million), or 11.6% of net revenues for the same period in 2011.

Operating income.  Operating income was RMB117.3 million (US$18.7 million) for the first nine months of 2012, a 22.8% increase from operating income of RMB95.6 million (US$15.0 million) for the same period in 2011. Operating margin for the first nine months of 2012 was 23.1%, a 0.7% point decline from operating margin of 23.8% for the same period in 2011. The decline in operating margin is primarily due to increased R&D expenses. 

Interest income. Net interest income was RMB18.4 million (US$2.9 million) for the first nine months of 2012, compared to RMB13.8 million (US$2.2 million) for the same period in 2011. The increase is primarily due to the combined effect of increased time deposits and higher interest rates on time deposits.

Net income attributable to 3SBio Inc. GAAP Net income attributable to 3SBio Inc. was RMB85.2 million (US$13.6 million) for the first nine months of 2012, a 1.1% decrease over net income of RMB86.2 million (US$13.5 million) for the same period in 2011. Net income attributable to 3SBio Inc. per ADS on a fully-diluted basis for the first nine months of 2012 decreased to RMB3.76 (US$0.60) compared to RMB3.83 (US$0.60) for the same period in 2011. Net margin for the first nine months of 2012 was 16.7%, a 4.8% point decrease over net margin of 21.5% for the same period in 2011.

Non-GAAP net income attributable to 3SBio Inc. was RMB105.7 million (US$16.8 million) for the first nine months of 2012, a 22.5% increase over net income of RMB86.2 million (US$13.5 million) for the same period in 2011. Non-GAAP net income attributable to 3SBio Inc. per ADS on a fully-diluted basis for the first nine months of 2012 increased to RMB4.65 (US$0.74) compared to RMB3.83 (US$0.60) for the same period in 2011. Non-GAAP net margin for the first nine months of 2012 was 20.9%, a 0.6% point decrease over net margin of 21.5% for the same period in 2011. 

The difference between GAAP and non-GAAP net income is due to writedowns of RMB 11.3 million (US$1.8 million) in the second quarter and RMB 9.1 million (US$1.45 million) in the third quarter in available-for-sale securities, following declines deemed to be other than temporary in the market value of 3SBio's US$4.5 million investment in the common shares of Isotechnika (TSX:ISA). The carrying value of the investment in Isotechnika as of September 30, 2012 was RMB7.9 million (US$1.3 million).

Conference Call

3SBio's senior management will host a conference call on Monday, November 12, 2012 9:00pm China Standard Time (8:00am US Eastern or 5:00am US Pacific) to discuss its unaudited third quarter 2012 results and recent business activity. The conference call may be accessed using the dial-in numbers below:

Conference ID: 39479759

Local dial-in:
China landline: 800-819-0121
China mobile: 400-620-8038
Hong Kong : 852-2475-0994
United States: 718-354-1231

International toll-free dial-in:
Hong Kong:  800930346
United States:  1-866-519-4004
United Kingdom:  080-8234-6646

International toll dial-in: 65 6723 9381

Replay- Conference ID: 39479759
A telephone replay will be available two hours after the call until November 20, 2012 at:
International:  61-2-8235-5000
United States: 1-866-214-5335

Webcast
A live webcast of the conference will be available on the investor relations section of 3SBio's website at
www.3sbio.com and at http://www.media-server.com/m/p/z3b7da4s.
A replay of the webcast will be available within one hour after the conclusion of the call.

Non-GAAP Financial Measures: Reconciliation of GAAP to Non-GAAP

To supplement the Company's financial information presented in accordance with general accepted accounting principles ("GAAP"), the Company has utilized some non-GAAP financial measures to provide investors and management with supplemental measures that facilitate comparisons of operating performance and trends with prior and future operating performance, and that may not otherwise be apparent on a GAAP basis. The non-GAAP financial measure represents non-GAAP net income. The measure may be different from non-GAAP financial measures used by other companies. The presentation of this financial information, which is not prepared under any comprehensive set of accounting rules or principals, is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with the Company's results of operations as determined in accordance with GAAP. These measures should only be used to evaluate the Company's results of operations in conjunction with the corresponding GAAP measures. Please see the attached reconciliation of GAAP to non-GAAP for an explanation of the amounts excluded to arrive at non-GAAP financial measures for the three-month periods ended September 30, 2011 and September 30, 2012 and for the nine-month periods ended September 30, 2011 and September 30, 2012.

Statement Regarding Unaudited Financial Information

The unaudited financial information set forth above is preliminary and subject to adjustments and modifications. The audited financial statements and related notes are to be included in the Company's annual report on Form 20-F for the year ending December 31, 2012. Adjustments and modifications to the financial statements may be identified during the course of the audit work, which could result in significant differences from this preliminary unaudited financial information.

Currency Convenience Translation

For the convenience of readers, certain RMB amounts have been translated into US dollars at the rate of RMB6.2848 to US$1.00, the noon buying rate for US dollars in effect on September 30, 2012 as set forth in the H.10 statistical release of the U.S. Federal Reserve Board.  A rate of 6.3780 was used for comparative purposes as of September 30, 2011, which was the noon buying rate for US dollars on that date for cable transfers of RMB per US dollar as certified for customs purposes by the Federal Reserve Bank of New York.

About 3SBio Inc.

3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China.  Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.  With headquarters and GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 800 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol "SSRX". Please see www.3SBio.com for more information.

Cautionary Statement concerning Forward Looking Statements

Certain statements in the disclosures of 3SBio, Inc. (the "Company" or "3SBio") for the third quarter of 2012 ("Disclosures") that are not purely historical in nature may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Disclosures include the press release, the conference call and any accompanying materials, and any other information issued, released or publicized by the Company with respect to the third quarter and the year of 2012.

These forward-looking statements address activities, events, conditions, or developments that we currently expect or anticipate to occur in the future, and may include, but may not be limited to, discussions and statements regarding: full year revenue target, business growth and prospects, product pricing trends, the estimated completion of new facilities, government policies and regulations and the impact thereof, market size or patient number or illness prevalence estimates, product development prospects, future pipeline progress, regulatory review, certification and approval prospects, operation plans and objectives, partnerships or collaborations and the outcome thereof, capital expense estimate, future operations and strategies. Forward-looking statements can be identified by such terminology as "believe," "expect," "plans," "strategy," "potential", "prospects," "forecast," "estimate," "project," "anticipate," "aim," "will" or "would", "may" or "might", and words, phrases, expressions, and usages of similar meaning or substance or the negative thereof.

Forward-looking statements are based on management's current assumptions, beliefs, expectations, and projections, in light of the information currently available, and actual results, performances, or achievements could differ materially from those implied or expressed by the forward-looking statements.  Among the factors that could cause actual results to differ from what the Company currently anticipates may include: regulatory actions such as adverse drug pricing adjustments; government procurement and reimbursement practice; other government policies and regulations;  receipt and timing of regulatory approvals for new facility, products and indications; issues impacting the new facility construction; competition from other domestic and foreign pharmaceutical companies; risks and uncertainties related to cooperation, joint venture, and partnerships; changes in China's healthcare insurance system; the segment market growth for our products; market acceptance of our products; hospital or patient demand for our products; progress of our clinical trials; our ability to enhance production, sales and distribution network and other aspects of operation; our ability to effectively protect intellectual property; changes in the healthcare industry in China; and fluctuations in general economic and business conditions in China.

For additional information on factors identified above and other risk factors, uncertainties and assumptions, please refer to the Company's filings with the Securities and Exchange Commission at www.sec.gov, and, in particular, "Introduction – Cautionary Statement concerning Forward Looking Statements", Item 3.D "Risk Factors", Item 5. "Operating and Financial Review and Prospects", and other applicable discussions in 3SBio's annual report on Form 20-F for the year ended December 31, 2011.

All the statements in the Disclosures speak as of the date of the initial release, even if subsequently made available on the 3SBio website or otherwise.  3SBio undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, subsequent events or otherwise, after the date of this press release.

Investor Contacts
Bo Tan
Chief Financial Officer

3SBio Inc.
Tel: + 86 24 2581-1820
[email protected]

Tom Folinsbee
Director of Investor Relations
3SBio Inc.
Tel: + 852 8191-6991
[email protected]

 

3SBio Inc.
Unaudited consolidated balance sheets
(expressed in thousands)


December 31, 2011


September 30, 2012


September 30, 2012


RMB


RMB


US$

Assets



(unaudited)


(unaudited)







Current assets












Cash and cash equivalents

245,813


354,808


56,455

Restricted cash

665


667


106

Time deposits with financial institutions

499,201


467,085


74,320

Accounts receivable, less allowance for doubtful accounts:






December 31, 2011 – RMB2,542; September 30, 2012 – RMB2,190(US$348)

113,949


141,465


22,509

Notes receivable

47,243


59,645


9,490

Inventories

27,604


34,259


5,451

Prepaid expenses and other receivables(including expenses prepaid to related  parties amounting to RMB6,000 and RMB1,250 (US$199 as of December 31, 2011 and September 30, 2012, respectively)

 

 

32,672


 

 

38,754


 

 

6,166

Available-for-sale securities

22,830


7,855


1,250

Amounts due from related parties

-


1,160


185

Deferred tax assets

2,750


1,832


291







Total current assets

992,727


1,107,530


176,223







Time deposits with financial institutions

20,000


30,000


4,773

Available-for-sale securities

10,848


11,332


1,803

Investment in non-consolidated affiliates

2,245


5,062


805

Property, plant and equipment, net

198,053


206,259


32,819

Prepaid  land use rights

17,448


17,036


2,711

Prepayment and noncurrent deposits

16,801


4,123


656

Intangible assets, net

49,615


46,839


7,453

Long term receivables, less allowance for doubtful accounts:






December 31, 2011 RMB818; September 30, 2012 RMB818 (US$130)

3,111


2,493


397

Deferred tax assets

262


277


44







Total assets

1,311,110


1,430,951


227,684







Liabilities and shareholders' equity












Current liabilities












Accounts payable

6,218


3,641


579

Deferred grant income

374


374


60

Accrued expenses and other payables

48,389


61,519


9,789

Income tax payable

8,894


2,094


333







Total current liabilities

63,875


67,628


10,761







Deferred grant income

2,029


10,420


1,658







Total liabilities

65,904


78,048


12,419







Shareholders' equity












Share capital - ordinary shares US$0.0001 par value, 500,000,000 shares

authorized, 154,473,159 and 154,577,456 issued and outstanding as of

December 31, 2011 and September 30, 2012, respectively

124


124


20

Additional paid-in capital

973,218


989,676


157,471

Accumulated other comprehensive loss

(126,290)


(120,566)


(19,185)

Retained earnings

387,317


472,564


75,192







Total shareholders' equity attributable to 3SBio Inc.

1,234,369


1,341,798


213,498

Non-controlling interest

10,837


11,105


1,767

Total shareholders' equity

1,245,206


1,352,903


215,265







Total liabilities and shareholders' equity

1,311,110


1,430,951


227,684


 

3SBio Inc.
Unaudited consolidated statements of income
(expressed in thousands, except per share, per ADS and other share and ADS data)

 


For the Three Months Ended


For the Three Months Ended


September 30, 2011


September 30, 2012


RMB

US$


RMB

US$


(unaudited)

(unaudited)


(unaudited)

(unaudited)

Net Revenues:






EPIAO

86,566

13,573


100,620

16,010

TPIAO

46,002

7,213


57,155

9,094

Intefen

1,305

205


1,339

213

Inleusin

563

88


661

105

Iron sucrose

7,107

1,114


9,080

1,445

Export

5,339

837


10,277

1,635

Others

483

76


1,427

227







Total net revenues

147,365

23,106


180,559

28,729

Cost of revenues

(13,228)

(2,074)


(18,726)

(2,980)







Gross profit

134,137

21,032


161,833

25,749







Operating expenses






Research and development costs

(  10,628)

(1,666)


( 21,148)

(3,365)

Sales, marketing and distribution expenses

(68,217)

(10,696)


(83,888)

(13,348)

General and administrative expenses

(15,482)

(2,427)


(18,832)

(2,996)

Grant income

304

48


96

15







Operating income

40,114

6,291


38,061

6,055







Interest income

5,024

788


5,849

931

Impairment loss on available-for-sale securities

-

-


(9,084)

(1,445)

Share of  income/(loss) in  non-consolidated affiliates

(801)

(126)


355

56

Other losses, net

(2,122)

(333)


(4,979)

(792)

Total other income/(loss), net

2,101

329


(7,859)

(1,250)







Income before income tax expense

42,215

6,620


30,202

4,805

Income tax expense

(8,448)

(1,325)


(8,035)

(1,278)

Net  income

33,767

5,295


22,167

3,527

Less: net income attributable to non-controlling interest

(50)

(8)


(93)

(15)

Net  income attributable to 3SBio Inc.

33,717

5,287


22,074

3,512







Net income attributable to 3SBio Inc. per share:






Basic

0.22

0.03


0.14

0.02

Diluted

0.21

0.03


0.14

0.02

Basic weighted average number of shares outstanding

153,432,948

153,432,948


154,618,237

154,618,237

Diluted weighted average number of shares outstanding

157,836,261

157,836,261


159,338,465

159,338,465







Net income attributable to 3SBio Inc. per ADS:






Basic

1.54

0.24


1.00

0.16

Diluted

1.50

0.23


0.97

0.15

Basic weighted average number of ADSs outstanding

21,918,993

21,918,993


22,088,320

22,088,320

Diluted weighted average number of ADSs outstanding

22,548,037

22,548,037


22,762,638

22,762,638

 

 

3SBio Inc.
Unaudited consolidated statements of income
(expressed in thousands, except per share, per ADS and other share and ADS data)

 


For the Nine Months Ended


For the Nine Months Ended


September30, 2011


September 30, 2012


RMB

US$


RMB

US$


(unaudited)

(unaudited)


(unaudited)

(unaudited)

Net Revenues:






EPIAO

235,542

36,930


284,847

45,323

TPIAO

126,033

19,761


159,619

25,398

Intefen

3,875

608


3,554

565

Inleusin

1,933

303


1,862

296

Iron sucrose

18,168

2,849


25,814

4,107

Export

14,085

2,208


26,256

4,178

Others

2,096

329


4,046

643







Total net revenues

401,732

62,988


505,998

80,510

Cost of revenues

(43,188)

(6,771)


(52,668)

(8,380)







Gross profit

358,544

56,217


453,330

72,130







Operating expenses






Research and development costs

(  29,064)

(4,557)


( 54,441)

(8,662)

Sales, marketing and distribution expenses

(188,891)

(29,616)


(227,254)

(36,159)

General and administrative expenses

(46,519)

(7,294)


(55,011)

(8,753)

Grant income

1,491

234


699

111







Operating income

95,561

14,984


117,323

18,667







Interest income

13,751

2,156


18,432

2,933

Impairment loss on available-for-sale securities

-

-


(20,427)

(3,250)

Share of  loss in non-consolidated affiliates

(781)

(122)


(610)

(97)

Other losses, net

(557)

(87)


(4,502)

(716)

Total other income/(loss), net

12,413

1,947


(7,107)

(1,130)







Income before income tax expense

107,974

16,931


110,216

17,537

Income tax expense

(21,693)

(3,401)


(24,701)

(3,930)

Net  income

86,281

13,530


85,515

13,607

Less: net income attributable to non-controlling interest

(50)

(8)


(268)

(43)

Net  income attributable to 3SBio Inc.

86,231

13,522


85,247

13,564







Net income attributable to 3SBio Inc. per share:






Basic

0.56

0.09


0.55

0.09

Diluted

0.55

0.09


0.54

0.09

Basic weighted average number of shares outstanding

153,053,866

153,053,866


154,568,524

154,568,524

Diluted weighted average number of shares outstanding

157,583,783

157,583,783


158,913,155

158,913,155







Net income attributable to 3SBio Inc. per ADS:






Basic

3.94

0.62


3.86

0.61

Diluted

3.83

0.60


3.76

0.60

Basic weighted average number of ADSs outstanding

21,864,838

21,864,838


22,081,218

22,081,218

Diluted weighted average number of ADSs outstanding

22,511,969

22,511,969


22,701,880

22,701,880

 

Reconciliations of GAAP net income to non-GAAP net income for the third quarter of 2011 and 2012
(in RMB thousands, unaudited)


Three months ended

September 30, 2011


Three months ended

September 30, 2012






GAAP

Adjustment

Non-GAAP


GAAP

Adjustment

Non-GAAP


RMB

US$

RMB

RMB

US$


RMB

US$

RMB

RMB

US$

Net income

33,717

5,287

-

33,717

5,287


22,074

3,512

9,084

31,158

4,957













The adjustment for the three months ended September 30, 2012 is for the exclusion of the impairment loss of US$1,445,000 (RMB9,084,000) on available-for-sale securities.

 

 

Reconciliations of GAAP net income to non-GAAP net income for the nine months of 2011 and 2012
(in RMB thousands, unaudited)

 


Nine months ended

September 30, 2011


Nine months ended

September 30, 2012






GAAP

Adjustment

Non-GAAP


GAAP

Adjustment

Non-GAAP


RMB

US$

RMB

RMB

US$


RMB

US$

RMB

RMB

US$

Net income

86,231

13,522

-

86,231

13,522


85,247

13,564

 

20,427

105,674

16,814













The adjustment for the nine months ended September 30, 2012 is for the exclusion of the impairment loss of US$3,250,000 (RMB20,427,000) on available-for-sale securities.

SOURCE 3SBio Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
Analytics is the foundation of smart data and now, with the ability to run Hadoop directly on smart storage systems like Cloudian HyperStore, enterprises will gain huge business advantages in terms of scalability, efficiency and cost savings as they move closer to realizing the potential of the Internet of Things. In his session at 16th Cloud Expo, Paul Turner, technology evangelist and CMO at Cloudian, Inc., will discuss the revolutionary notion that the storage world is transitioning from mere Big Data to smart data. He will argue that today’s hybrid cloud storage solutions, with commodity...
Cloud data governance was previously an avoided function when cloud deployments were relatively small. With the rapid adoption in public cloud – both rogue and sanctioned, it’s not uncommon to find regulated data dumped into public cloud and unprotected. This is why enterprises and cloud providers alike need to embrace a cloud data governance function and map policies, processes and technology controls accordingly. In her session at 15th Cloud Expo, Evelyn de Souza, Data Privacy and Compliance Strategy Leader at Cisco Systems, will focus on how to set up a cloud data governance program and s...
Roberto Medrano, Executive Vice President at SOA Software, had reached 30,000 page views on his home page - http://RobertoMedrano.SYS-CON.com/ - on the SYS-CON family of online magazines, which includes Cloud Computing Journal, Internet of Things Journal, Big Data Journal, and SOA World Magazine. He is a recognized executive in the information technology fields of SOA, internet security, governance, and compliance. He has extensive experience with both start-ups and large companies, having been involved at the beginning of four IT industries: EDA, Open Systems, Computer Security and now SOA.
The industrial software market has treated data with the mentality of “collect everything now, worry about how to use it later.” We now find ourselves buried in data, with the pervasive connectivity of the (Industrial) Internet of Things only piling on more numbers. There’s too much data and not enough information. In his session at @ThingsExpo, Bob Gates, Global Marketing Director, GE’s Intelligent Platforms business, to discuss how realizing the power of IoT, software developers are now focused on understanding how industrial data can create intelligence for industrial operations. Imagine ...
Every innovation or invention was originally a daydream. You like to imagine a “what-if” scenario. And with all the attention being paid to the so-called Internet of Things (IoT) you don’t have to stretch the imagination too much to see how this may impact commercial and homeowners insurance. We’re beyond the point of accepting this as a leap of faith. The groundwork is laid. Now it’s just a matter of time. We can thank the inventors of smart thermostats for developing a practical business application that everyone can relate to. Gone are the salad days of smart home apps, the early chalkb...
We certainly live in interesting technological times. And no more interesting than the current competing IoT standards for connectivity. Various standards bodies, approaches, and ecosystems are vying for mindshare and positioning for a competitive edge. It is clear that when the dust settles, we will have new protocols, evolved protocols, that will change the way we interact with devices and infrastructure. We will also have evolved web protocols, like HTTP/2, that will be changing the very core of our infrastructures. At the same time, we have old approaches made new again like micro-services...
Operational Hadoop and the Lambda Architecture for Streaming Data Apache Hadoop is emerging as a distributed platform for handling large and fast incoming streams of data. Predictive maintenance, supply chain optimization, and Internet-of-Things analysis are examples where Hadoop provides the scalable storage, processing, and analytics platform to gain meaningful insights from granular data that is typically only valuable from a large-scale, aggregate view. One architecture useful for capturing and analyzing streaming data is the Lambda Architecture, representing a model of how to analyze rea...
Docker is an excellent platform for organizations interested in running microservices. It offers portability and consistency between development and production environments, quick provisioning times, and a simple way to isolate services. In his session at DevOps Summit at 16th Cloud Expo, Shannon Williams, co-founder of Rancher Labs, will walk through these and other benefits of using Docker to run microservices, and provide an overview of RancherOS, a minimalist distribution of Linux designed expressly to run Docker. He will also discuss Rancher, an orchestration and service discovery platf...
SYS-CON Events announced today that Vitria Technology, Inc. will exhibit at SYS-CON’s @ThingsExpo, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Vitria will showcase the company’s new IoT Analytics Platform through live demonstrations at booth #330. Vitria’s IoT Analytics Platform, fully integrated and powered by an operational intelligence engine, enables customers to rapidly build and operationalize advanced analytics to deliver timely business outcomes for use cases across the industrial, enterprise, and consumer segments.
Today’s enterprise is being driven by disruptive competitive and human capital requirements to provide enterprise application access through not only desktops, but also mobile devices. To retrofit existing programs across all these devices using traditional programming methods is very costly and time consuming – often prohibitively so. In his session at @ThingsExpo, Jesse Shiah, CEO, President, and Co-Founder of AgilePoint Inc., discussed how you can create applications that run on all mobile devices as well as laptops and desktops using a visual drag-and-drop application – and eForms-buildi...
Containers and microservices have become topics of intense interest throughout the cloud developer and enterprise IT communities. Accordingly, attendees at the upcoming 16th Cloud Expo at the Javits Center in New York June 9-11 will find fresh new content in a new track called PaaS | Containers & Microservices Containers are not being considered for the first time by the cloud community, but a current era of re-consideration has pushed them to the top of the cloud agenda. With the launch of Docker's initial release in March of 2013, interest was revved up several notches. Then late last...
SYS-CON Events announced today that Dyn, the worldwide leader in Internet Performance, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Dyn is a cloud-based Internet Performance company. Dyn helps companies monitor, control, and optimize online infrastructure for an exceptional end-user experience. Through a world-class network and unrivaled, objective intelligence into Internet conditions, Dyn ensures traffic gets delivered faster, safer, and more reliably than ever.
CommVault has announced that top industry technology visionaries have joined its leadership team. The addition of leaders from companies such as Oracle, SAP, Microsoft, Cisco, PwC and EMC signals the continuation of CommVault Next, the company's business transformation for sales, go-to-market strategies, pricing and packaging and technology innovation. The company also announced that it had realigned its structure to create business units to more directly match how customers evaluate, deploy, operate, and purchase technology.
In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect at GE, and Ibrahim Gokcen, who leads GE's advanced IoT analytics, focused on the Internet of Things / Industrial Internet and how to make it operational for business end-users. Learn about the challenges posed by machine and sensor data and how to marry it with enterprise data. They also discussed the tips and tricks to provide the Industrial Internet as an end-user consumable service using Big Data Analytics and Industrial Cloud.
The explosion of connected devices / sensors is creating an ever-expanding set of new and valuable data. In parallel the emerging capability of Big Data technologies to store, access, analyze, and react to this data is producing changes in business models under the umbrella of the Internet of Things (IoT). In particular within the Insurance industry, IoT appears positioned to enable deep changes by altering relationships between insurers, distributors, and the insured. In his session at @ThingsExpo, Michael Sick, a Senior Manager and Big Data Architect within Ernst and Young's Financial Servi...
Performance is the intersection of power, agility, control, and choice. If you value performance, and more specifically consistent performance, you need to look beyond simple virtualized compute. Many factors need to be considered to create a truly performant environment. In his General Session at 15th Cloud Expo, Harold Hannon, Sr. Software Architect at SoftLayer, discussed how to take advantage of a multitude of compute options and platform features to make cloud the cornerstone of your online presence.
Even as cloud and managed services grow increasingly central to business strategy and performance, challenges remain. The biggest sticking point for companies seeking to capitalize on the cloud is data security. Keeping data safe is an issue in any computing environment, and it has been a focus since the earliest days of the cloud revolution. Understandably so: a lot can go wrong when you allow valuable information to live outside the firewall. Recent revelations about government snooping, along with a steady stream of well-publicized data breaches, only add to the uncertainty
The explosion of connected devices / sensors is creating an ever-expanding set of new and valuable data. In parallel the emerging capability of Big Data technologies to store, access, analyze, and react to this data is producing changes in business models under the umbrella of the Internet of Things (IoT). In particular within the Insurance industry, IoT appears positioned to enable deep changes by altering relationships between insurers, distributors, and the insured. In his session at @ThingsExpo, Michael Sick, a Senior Manager and Big Data Architect within Ernst and Young's Financial Servi...
PubNub on Monday has announced that it is partnering with IBM to bring its sophisticated real-time data streaming and messaging capabilities to Bluemix, IBM’s cloud development platform. “Today’s app and connected devices require an always-on connection, but building a secure, scalable solution from the ground up is time consuming, resource intensive, and error-prone,” said Todd Greene, CEO of PubNub. “PubNub enables web, mobile and IoT developers building apps on IBM Bluemix to quickly add scalable realtime functionality with minimal effort and cost.”
The Internet of Things (IoT) is rapidly in the process of breaking from its heretofore relatively obscure enterprise applications (such as plant floor control and supply chain management) and going mainstream into the consumer space. More and more creative folks are interconnecting everyday products such as household items, mobile devices, appliances and cars, and unleashing new and imaginative scenarios. We are seeing a lot of excitement around applications in home automation, personal fitness, and in-car entertainment and this excitement will bleed into other areas. On the commercial side, m...